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Hypertension increases expression of growth factors and MHC An ill-defined entity called chronic rejection or chronic
II in chronic allograft nephropathy. allograft nephropathy remains the leading cause of graft
Background. Hypertension of the recipient is strongly asso- loss after the first year of transplantation, particularly ifciated with chronic allograft nephropathy. It is unclear, how-
death with a functioning graft is excluded as a cause ofever, whether hypertension is the cause or the consequence of
late graft failure [1]. Traditionally, the causes of chronicchronic allograft nephropathy.
Methods. The present study was performed in the Fisher to allograft nephropathy have been divided into alloantigen-
Lewis rat kidney transplant model. Transplanted rats (N  dependent (immunologic) and alloantigen-independent
eight in each group) received either no treatment or were made (nonimmunologic) factors. The former include major his-hypertensive by administration of deoxycorticosteron acetate
tocompatibility complex (MHC)-mismatching and acute(DOCA) and salt. Proteinuria and systolic blood pressure was
rejection episodes [2], the latter including hyperfiltrationmeasured monthly, grafts were harvested at 3 and 6 months
for semiquantitative reverse transcription-polymerase chain re- [3], conditions of the brain-death donor [4], and hyper-
action (RT-PCR) and for immunohistology. tension of the recipient. For many years, it has been known
Results. Systolic blood pressure was markedly elevated in
that hypertension is associated with graft failure. Cheighrats receiving DOCA/salt. Allografts of hypertensive animals
et al [5] reported that graft survival was significantly infe-contained significantly more cells expressing the proliferating
cell nuclear antigen compared to isografts and to allografts rior in hypertensive patients. Modena et al [6] observed an
from normotensive animals (P  0.05). Histologic staining and association between systolic and diastolic blood pressure
mRNA expression of major histocompatibility complex (MHC) and the pace of deterioration of graft function. Opelz,
II was markedly increased in allografts of hypertensive animals
Wujciak, and Ritz [7] reported a highly significant corre-compared to all other groups (P 0.05). Expression of mRNA
lation between posttransplant blood pressure and long-for platelet-derived growth factor-B (PDGF-B), transforming
growth factor- (TGF-) and collagen was higher in allografts term graft outcome in more than 29,000 patients. Reports
than in isografts and was highest in hypertensive animals. by Mange et al [8] confirmed these observations. In this
Conclusion. We conclude that hypertension augments the study, the relative risk for graft failure per 10 mm Hgexpression of growth factors in the allograft possibly aggravating
increase in mean arterial blood pressure was 1.30 [8].the intimal hyperplasia observed in chronic allograft nephropa-
An association between hypertension and deteriorationthy. By increasing the expression of MHC II antigens, hyperten-
sion may render the allograft more susceptible to alloantigen- of renal function does not prove a causal relationship
dependent damage. Hypertension and alloantigen-dependent since hypertension after transplantation might simply be
factors appear to exert additive or synergistic effects on in- the result of worsening graft function rather than viceflammatory pathways leading to graft injury.
versa. Retrospective studies cannot differentiate between
cause and effect. The first evidence that hypertension
per se may lead to graft damage was the observation
that not only hypertension after transplantation, but also
hypertension before transplantation is associated with
later chronic allograft nephropathy [9].
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Hypertension induces inflammatory changes in nativeathy, DOCA/salt.
kidneys, such as expression of intercellular adhesion mol-
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(PDGF-B) is observed before glomerulosclerosis devel- was snap-frozen for RNA isolation, one third was em-
bedded in paraffin, and one third was immersed in 3%ops [11]. Moreover, the immunosuppressive drug myco-
phenolate mofetil is able to attenuate renal injury in paraformaldehyde/100 mmol sucrose/100 mmol cacodyl-
ate overnight and then snap-frozen for immunohistology.this model [12], indicating that hypertension after renal
ablation causes renal injury through immune mecha-
Functional measurementsnisms. On the other hand, superimposed renovascular
hypertension aggravates renal damage in immunologic- The animals were placed in metabolic cages every 4
weeks for 24-hour urinary specimens. Proteinuria wasmediated renal diseases such as antiglomerular basement
membrane (GBM) nephritis [13] indicating that hyper- measured by the Bradford method (BioRad, Hercules,
CA, USA). Systolic blood pressure was determined un-tension acts synergistically with immunologic factors on
renal injury. To study the mechanisms by which hyper- der light ether anesthesia every 4 weeks by the tail-cuff
method.tension may contribute to chronic allograft nephropathy,
we investigated the effect of hypertension in a model of
Histologychronic rejection on renal pathology and expression of
growth factors known to contribute to renal damage. For semiquantitation of renal tissue damage, paraffin-
embedded sections were stained using the Azan-Mallory
method. The extent of interstitial and glomerular dam-
METHODS
age was scored semiquantitatively from 0 to 3 by an
Renal transplantation investigator unaware of the origin of the slide (J.J.). At
least five high-power fields were counted per section.Experiments were performed with male Fisher (F344)
and Lewis rats (Harlan-Winkelmann, Borchen, Ger- Staining for proliferating cell nuclear antigen (PCNA)
was performed on cryosections using a murine mono-many). Rats were housed in standard plastic cages and
maintained in a temperature- and humidity-controlled clonal antibody (MO8779, Dako, Hamburg, Germany).
PCNA-positive cells were counted in at least 10 high-environment. The animals had access to either standard
chow food or chow food containing 5% NaCl and tap power fields per section. MHC expression was assessed
by staining cryosections using a murine antibody againstwater ad libitum. The local governmental committee for
animal welfare approved the experiments. RT1Bu (OX-3, Biosource, Fleurus, Belgium). MHC ex-
pression was quantitated for at least 10 high-power fieldsRenal transplantation was performed as described pre-
viously [14]. F344 rats served as donors and Lewis rats as with the use of computer-based software (Meta View,
Universal Imaging, West Chester, PA, USA) as de-recipients. Under ether anesthesia, the left kidney was
isolated, excised, and perfused with cold University of scribed previously [15].
Washington (UW) solution. The kidney was transplanted
RNA isolation and reverse transcription-polymeraseorthotopically into a Lewis rat whose left kidney had
chain reaction (RT-PCR)been removed. Renal artery, vein, and ureter were anas-
tomosed end to end using 10-0 Prolene sutures. The Approximately 100 mg of renal tissue was homoge-
nized in 4 mol/L guanidine isothiocyanate (GITC) (Gibco,contralateral kidney was removed 10 days later. The ani-
mals received one subcutaneous dose of amoxicillin (20 BRL, Eggenstein, Germany). RNA was extracted by
ultracentrifugation through 5.7 mol/L caesium chloridemg/kg) after transplantation. All animals received subcu-
taneous cyclosporine A (1.5 mg/kg/day) for 10 days. (Gibco, BRL), quantitated by determining optical den-
sity at 260 and 280 nm and precipitated in ethanol [16].
Experimental protocol Equal amounts of RNA per animal and group were pooled
to account for interindividual variations yielding one poolFour groups of eight rats were studied. Groups 1 and
2 consisted of isografted rats and groups 3 and 4 consisted of RNA per group. Reverse transcription (RT) of 1 g
RNA into cDNA was performed using random hexamersof allografted rats. Animals of groups 2 and 4 received
high-salt chow food and 10 mg/week deoxycorticosteron- and avian myeloblastosis virus (AMV) reverse transcrip-
tase (Promega, Serva, Heidelberg, Germany). cDNA (100acetate (DOCA) administered subcutaneously (Sigma
Chemical Co., Deisenhofen, Germany). Four animals per ng) were amplified by polymerase chain reaction (PCR)
in a total volume of 30 L using 2.5 U Ampli-Taq DNAgroup were sacrificed at 3 months after transplantation,
the remaining four animals at 6 months after transplanta- polymerase (Perkin-Elmer-Cetus, Emeryville, CA, USA),
100mol/L deoxyadenosine triphosphate (dATP), deoxy-tion. At sacrifice, the aorta was cannulated with a 16
gauge needle under anesthesia with ether and ketamine cytadine triphosphate (dCTP), deoxyguanosine triphos-
phate (dGTP), and 50 mol/L deoxythymidine triphosphate(100 mg/kg, administered intraperitoneally). The kidney
was flushed with 50 mL phosphate-buffered saline (PBS) (dTTP) (Boehringer Mannheim, Mannheim, Germany)
and 0.5 mol/L of each primer in 1 PCR buffer [20and fixed in situ with 50 mL 3% paraformaldehyde in
PBS. The kidney was divided in three parts. One third mmol/L Tris-HCl, pH 8.3; 50 mmol/L KCl; 2 to 4 mmol/L
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Table 2. Proteinuria (mg/day, mean  SEM)Table 1. Systolic blood pressure (mm Hg, mean  SEM)
Isograft  Allograft  Isograft  Allograft 
Month Isograft hypertension Allografta hypertensionaMonth Isograft hypertension Allograft hypertension
1 855a,b 18015 955a 1808 1 102 102 91 102
2 81 91 197 912 859a,b 18015 979a 15716
3 863a,b 19017a 1216a 1456 3 71 145 134 92
4 112 101 2718 2674 1026a,b 1939a 1086a 1456
5 1026a,b 21340 1086a 1533 5 193 141 4713 334
6 112 122 6128 96516 926a,b 1486 1004a 1609
aP  0.01 for increase with timeaP  0.05 vs. allograft  hypertension; bP  0.05 vs. isograft  hypertension
MgCl; 100 g/mL bovine serum albumin (BSA)]. PCR Statistical analysis
products were compared in the linear phase of the reac-
Results are expressed as means  SEM. Differencestion when ethidium bromide staining is often too insensitive
between groups were compared using unpaired analysisto detect a signal. Therefore, incorporation of digoxi-
of variance (ANOVA) followed by Bonferroni testinggenin was performed by addition of 10 mol/L digoxi-
(Instat, GraphPad Software). A P value of 0.05 wasgenin-11-deoxyuridine triphosphate (dUTP) to the PCR
considered as significant.reaction mixture. Cycles included 1 minute each at 95C,
56C to 62C, and 72C in a microprocessor-driven ther-
mal cycler (Model 9700, Perkin-Elmer). Primers for glyc- RESULTS
eraldehydes-3-phosphate dehydrogenase (GAPDH) [17], Functional measurements
PDGF-B [18], transforming growth factor-1 (TGF-1)
Blood pressure was significantly higher in DOCA/salt–[19], vascular endothelial growth factor (VEGF) [20],
treated animals compared to untreated animals (Table 1).MHC class I [21], MHC class II [22], as well as 	1 chain
Within DOCA/salt–treated animals, blood pressure wasof collagen IV [23] were chosen using the software
significantly higher in isografted animals compared to“primer 3” [24]. Aliquots (10L) were taken after differ-
allografted animals at 3 and 4 months.ent numbers of cycles (at least two numbers of cycles)
Proteinuria increased significantly over time in allo-analyzed on 1.5% agarose gels and the PCR products
grafted animals, but not in isografted animals (Table 2).were stained with ethidium bromide. PCR products were
At 6 months, proteinuria was higher in DOCA/salt–treatedblotted onto nylon membranes (Amersham, Braunsch-
allografted animals compared to DOCA/salt–treatedweig, Germany) by capillary blotting using 20 standard
isografted animals, but this difference did not reach sig-sodium citrate (SSC) as blotting buffer [16]. The nylon
nificance. The serum creatinine was not significantly dif-membranes were fixed by ultraviolet light and the digoxi-
ferent between groups (Table 3) or compared to normalgenin-UTP that had been incorporated into the PCR
control rats (0.68  0.04 mg/dL, N  4).products was visualized by staining with antidigoxigenin
antibody conjugated to alkaline phosphatase (DIG Lumi-
Histology
nescent Detection Kit, Boehringer Mannheim). Lumi-
In all animals, PCNA expressing could be observed.nescence of the substrate [Lumigen purified protein
The number of PCNA-expressing cells/high-power fieldderivative (PPD)] was documented by short exposure to
was higher at 3 months than at 6 months (Table 4). Atx-ray film (Kodak, Rochester, NY, USA). After per-
3 months, allografts of hypertensive animals containedforming PCR for GAPDH for 28 and 32 cycles in preced-
significantly more PCNA-expressing cells compared toing experiments, the signal intensities for GAPDH-PCR
isografts and to allografts from normotensive animalsproducts were compared between groups (Scion Image
(P  0.05, Table 4). Most PCNA-expressing cells were1.62, NIH). The amount of cDNA taken for PCR was
tubular epithelial cells (Fig. 1), but glomerular mesangialadjusted until there was exactly the same signal for
cells also expressed PCNA.GAPDH in each group. The kinetics of the PCR reaction
Interstitial and glomerular fibrosis as determined bywas then determined for each mRNA target. The optimal
semiquantitative scoring from 0 to 3 was more pro-number of cycles enabling comparison of PCR products
nounced in allografts of hypertensive animals comparedin the linear phase of the reaction was carried out for
to all other groups (Table 4). This difference was signifi-each mRNA target separately. Every PCR reaction was
cant for both 3 and 6 months except for hypertensiveperformed at least three times to verify reproducibility
animals at 6 months (Table 4).of differences between groups.
In all groups, MHC expression was found to be higherFor PDGF-B, TGF-1, and VEGF, nested PCR was
at 3 months compared to 6 months. Histologic expressionperformed. After an initial round of 20 cycles using the
of MHC was largely increased in allografts of hyperten-5
 and 3
 primer, an additional round of 10 to 20 cycles
were performed using the internal and the 3
 primer. sive animals compared to all other groups both at 3
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Table 4. Immunohistologic expression of major histocompatibilityTable 3. Serum creatinine (mg/dL, mean  SEM)
complex (MHC) (arbitrary units), proliferating cell nuclear antigen
Isograft  Allograft  (PCNA) (positive cells/high-power field) and interstitial fibrosis
Month Isograft hypertension Allograft hypertension score (mean  SEM)
3 0.810.04 0.720.02 0.720.02 1.50.6 Isograft  Allograft 
6 0.80.02 0.780.06 0.760.01 0.80.03 Isograft hypertension Allograft hypertension
MHC II
3 months 44601132a 48191790a 74611337 111361861
6 months 811288a 32001496a 2560522a 88631192
PCNAmonths and at 6 months (Table 4). The difference be- 3 months 1.50.2a 1.070.2a 1.10.2a 3.90.5
tween allografts of hypertensive animals and the other 6 months 0.460.12 0.810.12 0.460.12 0.750.12
Fibrosisgroups was greater at 6 months than at 3 months. Several
3 months 1.30.1 0.90.2a 1.10.1a 1.70.2
cell types expressed MHC, including glomerular cells, 6 months 1.00.2a 1.10.2 1.00.1a 1.70.2
interstitial peritubular cells, and perivascular cells. MHC aP  0.05 vs. allograft  hypertension
expression was most pronounced in the perivascular
space while cells of the vascular wall itself did not express
MHC (Fig. 2). DISCUSSION
Several clinical studies confirmed an association be-
Gene expression of MHC and growth factors tween hypertension and subsequent chronic rejection
MHC I transcription was readily detectable in isografts [7–9]. Our data suggest that alloantigen-dependent and
and in allografts, while transcription of MHC II was alloantigen-independent factors share final pathways in
only observed in allografts (Fig. 2). When compared to the pathogenesis of chronic allograft nephropathy. Initia-
isografts, MHC gene expression was increased in allo- tion of the immune response with subsequent induction
grafts from both normotensive and hypertensive animals of growth factors, traditionally considered to be caused
(Fig. 2). Hypertension alone did not result in an increase by alloantigen-dependent factors such as acute rejection,
of MHC transcription in isografts, but hypertension did may also be part of the pathogenesis of graft injury by
augment transcription of MHC in allografts (Fig. 2). This alloantigen-independent factors such as hypertension.
effect was observed for both MHC I and MHC II, but Hypertension may act in addition to or synergistically
to a greater extent for MHC II. with alloantigen-dependent factors on inflammatory
Gene expression of PDGF-B, TGF-, VEGF, and col- pathways leading to graft injury.
lagen IV is shown in Figure 3. At 3 months, gene expres- The observed augmenting effect of DOCA/salt treat-
sion for PDGF-B was detected in allografts, but not ment on MHC expression in renal allografts is a new
in isografts. Treatment with DOCA/salt resulted in a observation that to our knowledge has not been de-
marked increase in PDGF-B expression at 3 months. At scribed before. The mechanism by which hypertension
6 months, gene expression of PDGF-B was observed in augments the expression of MHC in allografts is not
all groups, was slightly increased in allografts compared fully understood. A direct effect of the substance DOCA
to isografts, and was highest in allografts of hypertensive itself or of possibly contaminating endotoxin cannot be
animals (Fig. 3). At 3 months, TGF- expression could excluded. For instance, DOCA/salt treatment increases
not be detected in normotensive isografts but in hyper- blood pressure as well as fibrosis and TGF- expression
tensive isografts and in allografts. Similar to PDGF-B, in the heart [25, 26], but MHC expression was not re-
treatment with DOCA/salt resulted in an increase in ported in these studies. However, the distribution of
TGF- expression at 3 months. At 6 months, TGF- MHC II in the perivascular space indicates a direct pres-
expression was also detectable in normotensive isografts, sure effect, possibly involving fluid shear stress. In vitro,
but to a lower degree than in the other three groups. induction of MHC antigens by shear stress has been
Similar to the earlier time point, TGF- expression was reported in endothelial cells [27]. Abumiya et al [28]
highest in allografts of hypertensive animals, but the reported that in native kidneys of spontaneous hyperten-
difference between groups was less pronounced at 6 sive rats, accumulation of MHC II–positive macrophages
months compared to three months. Similar results were could be observed. Similar to our observations, these
observed for collagen IV. Expression of VEGF was ob- MHC II–positive macrophages were predominantly lo-
served in all groups. VEGF was expressed to a greater cated along the perivascular space. Interestingly, in the
extent in allografts compared to isografts at 3 months. present study DOCA/salt treatment did not induce MHC
Treatment with DOCA/salt had no influence on VEGF in isografts, whereas it readily augmented MHC expres-
expression. At 6 months, expression of VEGF was simi- sion in allografts. The fact that MHC expression was not
observed in isografts of hypertensive animals indicateslar in all groups.
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Fig. 1. Immunohistologic detection of proliferating cell nuclear antigen
(PCNA) 3 months after renal transplantation (A). The number of PCNA-
positive cells/high-power field (HPF) are shown in (B) (meanSEM). Ab-
breviations are: Iso, isograft; Allo, allograft; Tx, transplantation. *P 0.05.
that hypertension alone is not sufficient to induce MHC
Fig. 2. Immunohistologic detection (A ) and mRNA expression [re-
in this model. Allotransplantation appears to be a pre- verse transcription-polymerase chain reaction (RT-PCR)] (B ) of major
histocompatibility complex (MHC) II 3 months after renal transplanta-requisite for MHC expression. There appear to be addi-
tion. The numbers indicate the ratio MHC:glyceraldehyde-3-phosphatetive or synergistic effects of hypertension and alloanti-
dehydrogenase (GAPDH) determined by densitometry compared to iso-
gen-dependent mechanisms on MHC expression. Thus, grafts (Iso) (1.0). Abbreviations are: Allo, allograft; Tx, transplantation.
hypertension may increase the immunogenicity of renal
allografts, predisposing the graft to immunologic injury
and the development of acute rejection episodes. Re- phropathy would substantiate the causal link between
hypertension and acute rejections of renal allografts.cently, Cosio et al [29] reported that hypertensive pa-
tients are at increased risk even for acute rejection epi- One of the hallmarks of chronic rejection is the devel-
opment of smooth muscle cell proliferation resulting insodes. The authors speculated that conditions of the graft
(ischemia, delayed graft function) predisposing to acute an extensive neointima and obliteration of the vessel
lumen. One of the key mediators of smooth muscle cellrejections also lead to elevated blood pressure. The pres-
ent study indicates that, on the other hand, hypertension proliferation is PDGF. PDGF, along with TGF-, inter-
leukin-1 (IL-1), and insulin-like growth factor (IGF) ismay augment expression of MHC and growth factors
and therefore predispose for acute rejection. However, mitogenic for smooth muscle cells and is involved in
the vascular response to injury. PDGF is induced bythe present study is limited because we did not provide
a group of DOCA/salt–treated animals receiving antihy- hypertension in spontaneously hypertensive [30] and in
DOCA-treated [31] rats, as well as by ischemia [32].pertensives. The demonstration that lowering blood pres-
sure in DOCA/salt–treated rats reduces MHC and growth PDGF could also be identified in experimental models
of acute and chonic rejection. Alpers et al [33] observedfactor expression and ameliorates chronic allograft ne-
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only well-established model for chronic rejection, it is
limited since it cannot reproduce the clinical picture in
every aspect.
It is possible that antihypertensive treatment may re-
duce the development of chronic allograft nephropathy.
This hypothesis is supported by studies in animals show-
ing that blockers of the action of angiotensin II protects
from chronic rejection [38, 39] but clinical data are scarce.
Rahn et al [40] demonstrated that treatment with nitren-
dipine results in better renal function after 2 years, but
this study included only 103 patients and was too short
to assess long-term benefits on chronic allograft nephropa-
thy. Until clinical studies are performed, it is necessary to
emphasize the importance of controlling hypertension,
maybe even more so after than before transplantation.
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